Biogen is eliminating corporate infrastructure that had been put in place to support sales of Aduhelm (aducanumab) in the U.S., the company announced. The decision is being made in response to a policy announced last month that Medicare would only cover the cost of Aduhelm for people with Alzheimer’s disease enrolled in select clinical trials. The decision has outraged patient advocacy groups. “We are disappointed by the recent Medicare coverage decision for Aduhelm,” Michel Vounatsos, Biogen’s…
May 06, 2022May 6, 2022